[Regional intraosseous thrombolytic therapy in comprehensive treatment of patients with diabetic foot syndrome].
The authors assessed efficacy of regional intraosseous administration of urokinase medac in comprehensive treatment of patients with complicated forms of diabetic foot syndrome by means of analysing therapeutic results in a total of 65 patients presenting with pyonecrotic complications of diabetic foot. The patients were subdivided into 2 groups. The control group was composed of 35 patients receiving basic therapy. The study group comprised 30 patients subjected to comprehensive treatment including regional intraosseous (into the heel bone of the affected limb) administration of urokinase medac at a dose of 100 thousand IU for 5 days. Efficacy of treatment was evaluated by the course of the wound process, indices of haemostasis, free radical oxidation, results of surgical treatment. In patients of the Study Group the terms of wound purification from pyonecrotic masses amounted to 9.8±0.3 days, which was by 4.7 days less than in the Control Group patients (p<0.01), marginal epithelialization of wounds also occurred averagely by 6.4 days faster. On day 22 of using the basic therapy alone, the haemostasis system preserved the condition of coagulation activity. The Study Group patients as early as on day 5 of treatment demonstrated shifts towards normocoagulation. In the Control Group by day 22 of treatment, the level of malonic dialdehyde decreased by 18.5%, the index of catalase activity increased by 24.6% (p<0.05); in the Study Group the level of malonic dialdehyde decreased by 42.6% and catalase activity increased by 69.4% (p<0.01). On the background of using urokinase the number of high amputations decreased by 18% and the number of operations with the supporting function preserved decreased by 12% as compared with basic therapy alone. A conclusion was made that additional use of regional intraosseous administration of urokinase medac as compared with basic therapy alone promoted a more significant decrease in the coagulation activity of blood and the level of free-radical lipid oxidation, stimulation of regenerative processes, as well as improvement of outcomes of surgical treatment.
Chair of General Surgery named after Professor N.I. Atyasov, Medical Institute, Mordovia State University named after N.P. Ogarev, Saransk, Russia.
A N
AN
Beliaev
Chair of General Surgery named after Professor N.I. Atyasov, Medical Institute, Mordovia State University named after N.P. Ogarev, Saransk, Russia.
A N
AN
Rodin
Chair of General Surgery named after Professor N.I. Atyasov, Medical Institute, Mordovia State University named after N.P. Ogarev, Saransk, Russia.
S A
SA
Kozlov
D000671:Amputation, Surgical / Q000379:methods / Q000706:statistics & numerical data; D017719:Diabetic Foot / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D017148:Infusions, Intraosseous / Q000379:methods; D035002:Lower Extremity / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010084:Oxidation-Reduction / Q000187:drug effects; D012189:Retrospective Studies; D012426:Russia; D013492:Suppuration / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects; D014945:Wound Healing / Q000187:drug effects
D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator